TrialGut and liver2023

A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 mg in Patients with Nonerosive Gastroesophageal Reflux Disease.

Su Hyun Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.